Mobile

26-week open-label extension study evaluating the safety and tolerability of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia

Update Il y a 4 ans
Reference: EUCTR2005-005502-23

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To assess the safety and tolerability of oral ziprasidone (40-80 mg BID) during long-term, open-label administration in adolescent subjects with schizophrenia.

Inclusion criteria

  • Schizophrenia

Links